NASDAQ:KERX Keryx Biopharmaceuticals (KERX) Stock Price, News & Analysis → Exposed: How Big Banks Plan to Chain Your Wealth with Digital Dollars (From GoldenCrest Metals) (Ad) Free KERX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$2.97▼$3.4750-Day Range N/A52-Week Range$2.47▼$5.98Volume2.60 million shsAverage Volume1.69 million shsMarket Capitalization$344.00 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Keryx Biopharmaceuticals alerts: Email Address Ad GoldenCrest MetalsExposed: How Big Banks Plan to Chain Your Wealth with Digital DollarsBig Banks have declared war on your wallet. But it's not too late to fight back. Discover how to protect your assets from their latest maneuver.Learn More Now About Keryx Biopharmaceuticals Stock (NASDAQ:KERX)Keryx Biopharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on providing medicines for patients with kidney disease in the United States. It markets its lead product Auryxia (ferric citrate), an orally available, absorbable, iron-based medicine for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis, as well as for the treatment of iron deficiency anemia in adults with CKD not on dialysis. The company has strategic alliances with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of ferric citrate in Japan; and with Panion & BF Biotech, Inc. for the development and marketing of ferric citrate. Keryx Biopharmaceuticals, Inc. was founded in 1997 and is headquartered in Boston, Massachusetts.Read More Ad GoldenCrest MetalsExposed: How Big Banks Plan to Chain Your Wealth with Digital DollarsBig Banks have declared war on your wallet. But it's not too late to fight back. Discover how to protect your assets from their latest maneuver.Learn More Now KERX Stock News HeadlinesApril 13, 2024 | morningstar.comCaliway Biopharmaceuticals Co Ltd 6919November 15, 2023 | morningstar.comXTL Biopharmaceuticals Ltd ADR XTLBApril 24, 2024 | GoldenCrest Metals (Ad)Exposed: How Big Banks Plan to Chain Your Wealth with Digital DollarsBig Banks have declared war on your wallet. But it's not too late to fight back. Discover how to protect your assets from their latest maneuver.September 11, 2023 | investing.comImmuneOnco Biopharmaceuticals Shanghai Inc (1541)August 13, 2023 | finance.yahoo.comQ2 2023 Westrock Coffee Co Earnings CallJuly 29, 2023 | thestreet.comKeryx CEO vs. a Short-Seller: Zerenex Patent DebateMay 12, 2023 | marketwatch.com8-K: CUTERA INCMay 6, 2023 | seekingalpha.comManoj MadhavanApril 24, 2024 | GoldenCrest Metals (Ad)Exposed: How Big Banks Plan to Chain Your Wealth with Digital DollarsBig Banks have declared war on your wallet. But it's not too late to fight back. Discover how to protect your assets from their latest maneuver.May 3, 2023 | finance.yahoo.comBiopharmaceuticals Market Size [2023-2030] | Industry Share, Revenue, Key Players, CAGR, Demand and ForecastApril 13, 2023 | wsj.comStaidson (Beijing) Biopharmaceuticals Co. Ltd.March 28, 2023 | finance.yahoo.comBiopharmaceuticals Market Growth: Worth $700Bn by 2028 Led by Monoclonal Antibodies Held Market Share of 48.42% in 2022 | The Insight PartnersJanuary 29, 2023 | marketwatch.comBiopharmaceuticals Market 2023 Analysis by Market Size, New Technology, Growth Rate, Geographical Regions, Drivers and Outlook to 2027January 25, 2023 | seekingalpha.comNAVB Navidea Biopharmaceuticals, Inc.January 25, 2023 | finance.yahoo.comBiopharmaceuticals Contract Manufacturing Market - Growth, Trends, COVID-19 Impact, and Forecasts (2023 - 2028)September 15, 2022 | thestreet.comWell-Fed Analysts Stay Mum on Keryx Biopharma's Slow Drug LaunchOctober 26, 2021 | finance.yahoo.comKeryx (KERX) Q1 Loss Wider than Expected, Revenues BeatJuly 29, 2021 | au.finance.yahoo.comTwitter tests notification banner for suspended and locked accountsJuly 29, 2021 | yahoo.comJoey Jordison, Slipknot co-founder and longtime drummer, dies at age 46July 28, 2021 | uk.finance.yahoo.comWhy Starbucks (SBUX) Might Surprise This Earnings SeasonJuly 27, 2021 | uk.finance.yahoo.comUN: World leaders can attend annual UN meeting in personJuly 27, 2021 | nz.finance.yahoo.comCreekstone Farms Meats Sizzle on Yoder Smokers With New PartnershipJuly 27, 2021 | au.finance.yahoo.comMidtown, Atlanta Based Innovien Solutions Continues Growth StreakJuly 27, 2021 | nz.finance.yahoo.comJill Biden Made This Versatile Bag Sell Out, and She Just Wore It AgainJuly 27, 2021 | yahoo.comIt's Your Business | More improvements on tap for Target on North ProspectSee More Headlines Receive KERX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Keryx Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/08/2018Today4/24/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:KERX CUSIP49251510 CIK1114220 Webwww.keryx.com Phone617-466-3500FaxN/AEmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-163,440,000.00 Net Margins-96.41% Pretax MarginN/A Return on EquityN/A Return on Assets-60.05% Debt Debt-to-Equity RatioN/A Current Ratio2.21 Quick Ratio1.19 Sales & Book Value Annual Sales$60.64 million Price / Sales5.67 Cash FlowN/A Price / Cash FlowN/A Book Value($0.12) per share Price / Book-28.00Miscellaneous Outstanding Shares102,380,000Free FloatN/AMarket Cap$344.00 million OptionableOptionable Beta2.35 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMs. Jodie Pope Morrison (Age 43)Interim CEO & Director Mr. Scott A. Holmes (Age 44)CFO, Sr. VP & Treasurer Ms. Christine A. Carberry (Age 57)Sr. VP & COO Dr. John F. Neylan (Age 65)Sr. VP & Chief Medical Officer Mr. Tony ChambersVP of SalesKey CompetitorsXOMANASDAQ:XOMAVanda PharmaceuticalsNASDAQ:VNDALexicon PharmaceuticalsNASDAQ:LXRXVerastemNASDAQ:VSTMMerrimack PharmaceuticalsNASDAQ:MACKView All Competitors KERX Stock Analysis - Frequently Asked Questions How were Keryx Biopharmaceuticals' earnings last quarter? Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) issued its quarterly earnings results on Thursday, November, 8th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.01. The biopharmaceutical company earned $28.04 million during the quarter, compared to the consensus estimate of $29.56 million. What other stocks do shareholders of Keryx Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Keryx Biopharmaceuticals investors own include Synergy Pharmaceuticals (SGYP), Amyris (AMRS), Gilead Sciences (GILD), Exelixis (EXEL), Immunomedics (IMMU), Novavax (NVAX), Akebia Therapeutics (AKBA), Ariad Pharmaceuticals (ARIA), Chesapeake Energy (CHKAQ) and Celldex Therapeutics (CLDX). This page (NASDAQ:KERX) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 Mediatop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsHow to camouflage a factory of 53,000 workersStansberry ResearchDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingEmergency: Biden's $20 Trillion Mistake Could Cost YOU!GoldenCrest MetalsThe #1 Crypto for 2024InvestorPlaceMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Keryx Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
